Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors

(2023) Feng Deng et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug‐drug interaction mediated by P‐Glycoprotein

(2022) Ludovic Lafaie et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

(2022) Dominique Farge et al.   LANCET ONCOLOGY

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation

(2022) Sutee Limcharoen et al.   Biomedicines

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation

(2021) Alenka Mavri et al.   Scientific Reports

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

(2020) Sarah Hanigan et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

(2019) Wonkyung Byon et al.   CLINICAL PHARMACOKINETICS

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

(2018) Venkatesh Pilla Reddy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study

(2013) Xavier Delavenne et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS